RT Journal Article
SR Electronic
T1 Interpreting the Jupiter trial: Statins can prevent VTE, but more study is needed
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 191
OP 194
DO 10.3949/ccjm.77a.09077
VO 77
IS 3
A1 Alejandro Perez
A1 John R. Bartholomew
YR 2010
UL http://www.ccjm.org/content/77/3/191.abstract
AB Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE.